Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EBT (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EBT for 11 consecutive years, with -$117.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT changed N/A to -$117.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$141.4 million, a N/A change, with the full-year FY2025 number at -$151.9 million, down 288.56% from a year prior.
  • EBT was -$117.9 million for Q4 2025 at Crescent Biopharma, down from -$2.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$2.3 million in Q1 2025 to a low of -$117.9 million in Q4 2025.
  • A 5-year average of -$17.6 million and a median of -$10.7 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 86.28% in 2021, then surged 78.17% in 2025.
  • Crescent Biopharma's EBT stood at -$17.4 million in 2021, then soared by 41.2% to -$10.2 million in 2022, then rose by 11.38% to -$9.1 million in 2023, then fell by 21.71% to -$11.0 million in 2024, then crashed by 966.82% to -$117.9 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's EBT are -$117.9 million (Q4 2025), -$2.3 million (Q1 2025), and -$11.0 million (Q3 2024).